FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087780877> ?p ?o ?g. }

• W2087780877 endingPage "2011.e2" @default.
• W2087780877 startingPage "2002" @default.
• W2087780877 abstract "To evaluate the safety, efficacy, and durability of bevacizumab for the treatment of subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD).Open-label, single-center, uncontrolled clinical study.Age-related macular degeneration patients with subfoveal CNV (n = 18) and best-corrected visual acuity (VA) letter scores of 70 to 20 (approximate Snellen equivalent, 20/40-20/400).Patients were treated at baseline with an intravenous infusion of bevacizumab (5 mg/kg) followed by 1 or 2 additional doses given at 2-week intervals. Safety assessments were performed at all visits. Ophthalmologic evaluations included protocol VA measurements, ocular examinations, and optical coherence tomography (OCT) imaging at each visit. Retreatment with bevacizumab was performed if there was evidence of recurrent CNV.Assessments of safety and changes from baseline in VA scores and OCT measurements were performed through 24 weeks.No serious ocular or systemic adverse events were identified through 24 weeks. The only adverse event identified was a mild elevation of mean systolic and diastolic blood pressure measurements (+11 mmHg, P = 0.004; +8 mmHg, P<0.001) evident by 3 weeks and easily controlled with antihypertensive medications. By 24 weeks, the systolic and diastolic mean blood pressures were at or below baseline measurements. Visual acuity in the study eyes improved within the first 2 weeks, and by 24 weeks, the mean VA letter score increased by 14 letters in the study eyes (P<0.001), and the mean OCT central retinal thickness measurement decreased by 112 microm (P<0.001). By 24 weeks, retreatment was needed for only 6 of the 18 study eyes, and after retreatment, the recurrent leakage was eliminated, with restoration of any lost VA.Systemic bevacizumab therapy for neovascular AMD was well tolerated and effective for all 18 patients through 24 weeks. By 6 months, most patients did not require any additional treatment beyond the initial 2 or 3 infusions. Despite these impressive results, it is unlikely that systemic bevacizumab will be studied in a large clinical trial because of the potential risks associated with systemic anti-VEGF therapy and the perception that intravitreal therapy is safer." @default.
• W2087780877 created "2016-06-24" @default.
• W2087780877 creator A5006650271 @default.
• W2087780877 creator A5012927829 @default.
• W2087780877 creator A5024868560 @default.
• W2087780877 creator A5036826547 @default.
• W2087780877 creator A5069179612 @default.
• W2087780877 creator A5087700840 @default.
• W2087780877 creator A5087754502 @default.
• W2087780877 date "2006-11-01" @default.
• W2087780877 modified "2023-10-10" @default.
• W2087780877 title "Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration" @default.
• W2087780877 cites W1513613431 @default.
• W2087780877 cites W1539571840 @default.
• W2087780877 cites W1601975653 @default.
• W2087780877 cites W1802218256 @default.
• W2087780877 cites W1968609549 @default.
• W2087780877 cites W1970142574 @default.
• W2087780877 cites W1972242350 @default.
• W2087780877 cites W1988688040 @default.
• W2087780877 cites W1995708259 @default.
• W2087780877 cites W2033245558 @default.
• W2087780877 cites W2058775052 @default.
• W2087780877 cites W2077129920 @default.
• W2087780877 cites W2081273617 @default.
• W2087780877 cites W2081633887 @default.
• W2087780877 cites W2143954917 @default.
• W2087780877 cites W2154711032 @default.
• W2087780877 cites W2160801689 @default.
• W2087780877 cites W2233259956 @default.
• W2087780877 doi "https://doi.org/10.1016/j.ophtha.2006.05.070" @default.
• W2087780877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17027972" @default.
• W2087780877 hasPublicationYear "2006" @default.
• W2087780877 type Work @default.
• W2087780877 sameAs 2087780877 @default.
• W2087780877 citedByCount "174" @default.
• W2087780877 countsByYear W20877808772012 @default.
• W2087780877 countsByYear W20877808772013 @default.
• W2087780877 countsByYear W20877808772014 @default.
• W2087780877 countsByYear W20877808772015 @default.
• W2087780877 countsByYear W20877808772016 @default.
• W2087780877 countsByYear W20877808772017 @default.
• W2087780877 countsByYear W20877808772018 @default.
• W2087780877 countsByYear W20877808772019 @default.
• W2087780877 countsByYear W20877808772021 @default.
• W2087780877 countsByYear W20877808772022 @default.
• W2087780877 crossrefType "journal-article" @default.
• W2087780877 hasAuthorship W2087780877A5006650271 @default.
• W2087780877 hasAuthorship W2087780877A5012927829 @default.
• W2087780877 hasAuthorship W2087780877A5024868560 @default.
• W2087780877 hasAuthorship W2087780877A5036826547 @default.
• W2087780877 hasAuthorship W2087780877A5069179612 @default.
• W2087780877 hasAuthorship W2087780877A5087700840 @default.
• W2087780877 hasAuthorship W2087780877A5087754502 @default.
• W2087780877 hasConcept C118487528 @default.
• W2087780877 hasConcept C126322002 @default.
• W2087780877 hasConcept C141071460 @default.
• W2087780877 hasConcept C197934379 @default.
• W2087780877 hasConcept C2776403814 @default.
• W2087780877 hasConcept C2776694085 @default.
• W2087780877 hasConcept C2777802072 @default.
• W2087780877 hasConcept C2778257484 @default.
• W2087780877 hasConcept C2781092963 @default.
• W2087780877 hasConcept C2781359195 @default.
• W2087780877 hasConcept C71924100 @default.
• W2087780877 hasConcept C84393581 @default.
• W2087780877 hasConceptScore W2087780877C118487528 @default.
• W2087780877 hasConceptScore W2087780877C126322002 @default.
• W2087780877 hasConceptScore W2087780877C141071460 @default.
• W2087780877 hasConceptScore W2087780877C197934379 @default.
• W2087780877 hasConceptScore W2087780877C2776403814 @default.
• W2087780877 hasConceptScore W2087780877C2776694085 @default.
• W2087780877 hasConceptScore W2087780877C2777802072 @default.
• W2087780877 hasConceptScore W2087780877C2778257484 @default.
• W2087780877 hasConceptScore W2087780877C2781092963 @default.
• W2087780877 hasConceptScore W2087780877C2781359195 @default.
• W2087780877 hasConceptScore W2087780877C71924100 @default.
• W2087780877 hasConceptScore W2087780877C84393581 @default.
• W2087780877 hasIssue "11" @default.
• W2087780877 hasLocation W20877808771 @default.
• W2087780877 hasLocation W20877808772 @default.
• W2087780877 hasOpenAccess W2087780877 @default.
• W2087780877 hasPrimaryLocation W20877808771 @default.
• W2087780877 hasRelatedWork W2009572462 @default.
• W2087780877 hasRelatedWork W2076711558 @default.
• W2087780877 hasRelatedWork W2616362931 @default.
• W2087780877 hasRelatedWork W2991715136 @default.
• W2087780877 hasRelatedWork W2991939470 @default.
• W2087780877 hasRelatedWork W2993662524 @default.
• W2087780877 hasRelatedWork W3027684582 @default.
• W2087780877 hasRelatedWork W3109830721 @default.
• W2087780877 hasRelatedWork W3149813528 @default.
• W2087780877 hasRelatedWork W4251170123 @default.
• W2087780877 hasVolume "113" @default.
• W2087780877 isParatext "false" @default.
• W2087780877 isRetracted "false" @default.
• W2087780877 magId "2087780877" @default.
• W2087780877 workType "article" @default.